|
13. Lauman
MK,Mortimer J. Effect of pyridoxine on the incidence of
palmar-plantar erythroderma (PPE) in patients receiving capecitabine.
Proc ASCO 2001; Abstract
1565.
14. Chin
SF et al. Use of “bag balm ” as topical treatment
of palmar-plantar erythrodysesthesia syndrome (PPES) in patients
receiving selected chemotherapeutic agents. Proc ASCO
2001; Abstract
1632.
15. Blum
JL et al. Multicenter phase II study of capecitabine in
paclitaxel-
refractory metastatic breast cancer. J Clin Oncol
1999;17:485-93. Abstract
16. Blum
JL. The role of capecitabine,an oral,enzymatically activated
fluoropyrimidine,in the treatment of metastatic breast cancer.
Oncologist
2001;6:56-64. Abstract
17. Gradishar
WJ. Clinical status of capecitabine in the treatment of
breast cancer. Oncology (Huntingt) 2001;15:69-71;discussion
72. Abstract
18. Kusama
M et al. A phase II study of Xeloda ™ ((capecitabine)in
patients with advanced/metastatic breast carcinoma —
The Cooperative Study
Group of Capecitabine for Breast Carcinoma. Proc ASCO
2001;
Abstract
1924.
19. Meza
LA et al. A phase II study of capecitabine in combination
with
paclitaxel as first-or second-line therapy in patients with
metastatic
breast cancer (MBC). Proc ASCO 2001; Abstract
2029.
20. Michaud
LB et al. Improved therapeutic index with lower dose
capecitabine in metastatic breast cancer (MBC) patients (Pts).
Proc ASCO
2000; Abstract
402.
21. O
’Shaughnessy J et al. A retrospective evaluation of
the impact of dose
reduction in patients treated with Xeloda (capecitabine).
Proc ASCO
2000; Abstract
400.
22. Piccart
MJ,Awada A. State-of-the-art chemotherapy for advanced
breast cancer. Semin Oncol 2000;27:3-12. Abstract
23. Procopio
G et al. A phase II study of capecitabine in elderly patients
with advanced breast cancer. Proc ASCO 2001; Abstract
3134.
24. Budman
DR et al. Preliminary studies of a novel oral fluoropyrimidine
carbamate:capecitabine. J Clin Oncol 1998;16:1795-802.
Abstract
25.Abushullaih
S et al. Characterizing hand-foot syndrome (HFS) caused
by capecitabine. Proc ASCO 2000; Abstract
2403.
|
